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Abstract: 
Natural inhibitors occupy an important place in the potential to neutralize the toxic effects caused by snake venom proteins and 
enzymes. It has been well recognized for several years that animal sera, some of the plant and marine extracts are the most potent 
in neutralizing snake venom phospholipase A2 (svPLA2). The implication of this review to update the latest research work which 
has been accomplished with svPLA2 inhibitors from various natural sources like animal, marine organisms presents a compilation 
of research in this field over the past decade and revisiting the previous research report including those found in plants. In addition 
to that the bioactive compounds/inhibitor molecules from diverse sources like aristolochic alkaloid, flavonoids and neoflavonoids 
from plants, hydrocarbones -2, 4 dimethyl hexane, 2 methylnonane, and 2, 6 dimethyl heptane obtained from traditional medicinal 
plants Tragia involucrata (Euphorbiaceae) member of natural products involved for the inhibitory potential of phospholipase A2 
(PLA2) enzymes in vitro and also decrease both oedema induced by snake venom as well as human synovial fluid PLA2. Besides 
marine natural products that inhibit PLA2 are manoalide and its derivatives such as scalaradial and related compounds, 
pseudopterosins and vidalols, tetracylne from synthetic chemicals etc. There is an overview of the role of PLA2 in inflammation 
that provides a rationale for seeking inhibitors of PLA2 as anti-inflammatory agents. However, more studies should be considered 
to evaluate antivenom efficiency of sera and other agents against a variety of snake venoms found in various parts of the world. 
The implications of these new groups of svPLA2 toxin inhibitors in the context of our current understanding of snake biology as 
well as in the development of new novel antivenoms therapeutics agents in the efficient treatment of snake envenomations are 
discussed. 
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Background: 
Snake envenomation is a serious medical problem, especially in 
the farms where snakes are abundant [1]. The common species 
such as Crotalus rhodostoma (38%), Trimeresurus albolabris (27%), 
Daboia russeli siamensis (14%), Naja atra (10%), and others (11%) 
are responsible for snakebites in Southeast Asia [2]. Snake 
venoms constitute a rich source of phospholipase A2 (PLA2) 
enzymes, which show remarkable functional diversity. Snake 
venom phospholipase A2 (svPLA2) can induce several 
additional effects such as cardiotoxicity, myotoxicity, pre or 
postsynaptic neurotoxicity, edema, hemolysis, hypotension, 
convulsion, platelet aggregation inhibition and anticoagulation 
[3-5]. svPLA2 catalyze the hydrolysis of 2-acyl ester bonds of 3-
sn-phospholipids producing fatty acids and lysophospholipids 
[6]. The Ca2+ ion, an essential cofactor, and an Asp residue at 
position 49 are required for catalysis on artificial substrates [6]. 
Their catalytic activity upon cell membranes of specific tissues 
suggests an important role of these enzymes in venoms toxicity. 
 
PLA2s were recently divided into 15 groups based on 
biochemical and structural criteria, considering their molecular 
weight, disulfide bonds profile, phospholipid substrates, amino 
acid sequence, and sensibility to Ca2+ ions, catalytic activity 
and genic structure [7-9]. Snake venoms are especially rich in BIOINFORMATION  open access 
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group I and II PLA2s, found in the Elapidae or Viperidae 
families, respectively. Group II PLA2s can be further subdivided 
into two main types commonly referred to as Asp-49 and Lys-
49 isoforms [10]. Since then, the isoforms of basic myotoxic 
PLA2s were isolated from Bothrops snakes and classified into 
group II, where the Asp-49 residue was replaced by Lys-49, 
resulting thus two classes of this enzyme: (a) Asp-49 myotoxins 
showing moderate catalytic activity and (b) Lys-49 myotoxins 
with low or no enzymatic activity upon artificial substrates [9-
10]. Previously, myonecrotic venom components were 
extensively studied. Several myotoxic Bothrops PLA2s were 
characterized, such as B. asper PLA2s, B. moojeni myotoxins I and 
II, and B. jararacussu bothropstoxins I (Lys-49) and II (Asp-49), 
responsible for several biological effects including myonecrosis, 
edema, irreversible neuromuscular blockage and in vitro cell 
lysis  [11-14] etc. Many acidic PLA2s have been isolated from 
Agkistrodon halys, Pseudechis papuanus, Bothrops neuwiedi, 
Bothrops lanceolatus, Trimeresurus jerdonii, Heloderma horridum, 
Ophiophagus hannah, Lachesis muta, B. jararaca, B. moojeni and B. 
jararacussu [15-19]. Toxicity and pharmacological effects differ 
in acidic isoforms. For example, the acidic PLA2 isolated from 
Lachesis muta venom is myonecrotic, proteolytic, anticoagulant 
and platelet aggregation inhibitor. Another myotoxic PLA2 from 
the same venom did not show anticoagulant or lethal activity. 
 
It has been suggested that PLA2s represent a class of versatile 
enzymes and, as multifunctional proteins; they are extremely 
relevant as mediators of several inflammatory diseases and 
promising agents for use in biotechnological areas [20-21]. An 
increasing search for use of these enzymes is therefore not 
surprising, including their general anesthetic action, treatment 
of rheumatoid arthritis, bactericidal action, novel class of 
antiparasitary agents, HIV inhibitors and others [22-26]. In this 
review, we broadly discuss the implications of the PLA2 
inhibitor groups of plants, marine organisms serve as sources of 
compounds on current understanding of snake biology, as well 
as in the development of new therapeutic drugs for treatment of 
snake envenomations. 
 
Venom neutralization by bio-active compounds from plant:  
a) Neutralization potential of crude mixture of plants 
Many plants are used in traditional medicine as active agents 
against various effects induced by snakebite [27]. Viperidae 
snakes (Daboia russelli russelli) are well known for sever local 
effects and these effects commonly treated with plant extracts 
without any scientific validation in triabl areas, India [28]. There 
are few survey reports that reveal the practice of herbal 
medicine by either folk or indigenous communities [29-31]. 
However, in most cases the efficacy of this traditional treatment 
regimen is unproven. Thus, the study of herbal antidotes 
against snake venom is of great importance in the management 
of snakebite. Recently, various research groups actively 
enganged for antivenom research by using diversed crude 
extracts and elucidated active compounds from various plants 
sources  [27, 32-34]. In addition, their natural PLA2 inhibitors 
also play an important role in some traditional medicines used 
for immune support, such as the ashwaganda plant (Withania 
somnifera) used in Ayurvedic medicine. Aqueous extracts of this 
plant have been reported to neutralize venom of the Indian 
speckled cobra -Naja naja  [35] Another report, ethanolic seed 
extract of Stychnos nux-vomica also showed antisnake venom 
activity [36]. Ethanol leaf extract of Acalypha indica potentially 
neutralized  Viper russelli russelli (Russell’s viper) venom [37]. 
Morus alba leaf extract abolished the in vitro proteolytic and 
hyaluronolytic activities of Indian vipera ‘Daboia russelli’ 
venom. Edema, hemorrhage and myonecrotic activities were 
also neutralized effectively [28]. Aqueous root extract of Mimosa 
pudica  inhibited the hyaluronidase and protease activities of 
Indian snake (Naja naja, Vipera russelli and Echis carinatus) 
venoms by dose dependant manner [38]. 
 
The ethanol leaf extract and essential oil of Nectandra angustifolia 
was the most active and inhibited both venom activities 
(hemolytic and coagulant), while the oil was only active on the 
coagulant activity [39]. Methanol extract of fresh leaves 
(Camellina sinensis L.) showed potential to inhibit PLA2 enzymes 
with hydrolytic activity in Naja naja kaouthia Lesson and 
Calloselasma rhodostoma Kuhl venoms [40]. Another, methanolic 
extract from Cordia verbenacea ‘baleeira’, ‘whaler’ (Cv) 
significantly inhibited paw edema induced by Bothrops 
jararacussu snake venom and by its main basic phospholipase A2 
homologs, namely bothropstoxins I and II (BthTXs). Alam et al, 
[41] also reported that the isolation, purification and partial 
characterization of viper venom inhibiting factor from the root 
extract of the Indian medicinal plant sarsaparilla (Hemidesmus 
indicus R.Br.). Viper venom-induced inflammation and 
inhibition of free radical formation by pure compound (2-
hydroxy-4-methoxy benzoic acid) isolated and purified from 
anantamul (Hemidesmus indicus R.BR) root extract [42]. 
 
In our previous study, the herbal practitioners in the study area 
were interviewed, and information on medicinal plants was 
collected from the traditional healers called “Vaidyars”. This 
survey covers 72 medicinal plants belonging to 53 families that 
are used for the treatment of snakebite in a traditional way. 
Traditional approach was evaluated scientifically with some 
selected plant extracts (7.2 mg/kg, bodoy weight) and partially 
purified fractions (2.4 mg/kg, b.w) were orally administered to 
mice experimentally envenomed with rattlesnake venom s.c. 
injection (2.5 - 15 mg/kg, b.w). Tested fractions (Aristolochia 
indica, Hemidesmus indicus, Gloriosa superba, Strychnos nux-
vomica, Eclipta prostrata, and Andrographis paniculata) showed 
potent neutralizing effect against the venom. Compared to the 
extracts, administration of purified fractions was more effective 
in increasing the body weight. Control mice injected with the 
venom alone showed weight loss and severe toxicity at 15 
mg/kg, b.w. The purified fractions (2.4 mg/kg, b.w) produced 
significant protection against venom induced changes in serum 
SOD and LPx levels. The isolated fractions effectively inhibited 
the toxic effect of snake venoms in vitro than in vivo. The above 
observations confirmed the protective activity of plants - 
Aristolochia indica, Hemidesmus indicus, Gloriosa superba, Strychnos 
nux-vomica, Eclipta prostrata, and Andrographis paniculata against 
the lethal action of snake venom [33]. 
 
Several plants are used in traditional medicine as active agents 
against various effects induced by snakebite [27, 32]. Folk 
medicine and its isolated constituents recommended as snake 
venom antidotes for the protection against Jararaca venom [43] 
for i.e. haemorrhagic effect of Bothrops atrox venom and their 
strong lethal enzymatic effect was neutralized by plants [44-45]. 
Furthermore, previoulsy we reported [33] hydrocarbones such 
as 2, 4 dimethyl hexane, 2 methylnonane, 2, 6 dimethyl heptane 
obtained from traditional medicinal plants Tragia involucrata BIOINFORMATION  open access 
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(Euphorbiaceae) member showed effective venom and PLA2 
neutralisation in mice (Figure 1A). PLA2  inhibitors have also 
been isolated from plants such as Horsfieldia amygdaline [46].  
 
 
Figure 1: Structure of various bioactive molucules involved for 
the inhibitory potential of phospholipase A2 (PLA2) enzymes in 
vitro and also decrease both oedema induced by snake venom 
as well as human synovial fluid PLA2.(A) Hydrocarbons like 2, 
4 dimethyl hexane, 2 methylonane, 2,6 dimethyl heptane 
obtained from traditional medicine plants Tragia involucrate 
(Euphorbiaceae) member (Samy et al,  J Ethnopharmacol. 
2006,107(1):99-106), (B) Aristolochic   alkaloid, (C) Flavonoids 
and neoflavonoids from plants (D) Manolide and scalaradial 
from marine sources (E) tetracylne (antibiotics) 
 
The active component was isolated and identified as rosmarinic 
acid (RA). RA is an ester of caffeic acid and 3, 4-
dihydroxyphenyllactic acid [2-O-cafeoil-3-(3, 4-di-hydroxy-
phenyl)-R-lactic [32]. RA in the species C. verbenacea and of its 
anti-inflammatory and antimyotoxic properties against snake 
venoms and isolated toxins reported for the first-time. RA 
inhibited the edema and myotoxic activity induced by the basic 
PLA2s BthTX-I and BthTX-II. The pure compound potentiated 
the ability of the commercial equine polyvalent antivenom in 
neutralizing lethal and myotoxic effects of the crude venom as 
well as isolated PLA2s in experimental models. Circular 
dichorism data also suggested that after binding, no significant 
conformation changes were occurred either in the Cv-RA or in 
the target PLA2. A possible model for the interaction of RA with 
Lys49-PLA2 BthTX-I is proposed [32]. A compound AIPLAI 
purified from the methanolic leaf extract of Azadirachta indica 
(Neem) inhibits the Cobra and Russell's viper venoms (RVVs) 
PLA2 enzymes in a dose-dependent manner and the AIPLAI 
holds good promise for the development of novel anti-snake 
venom drug in future [34].  
The secondary metabolites (chemical constituents) are 
responsible for the neutralizing effect of plants that are in 
popular use against the action of snake venoms [47-48]. An 
animal study has also been well documented in the case of 
immunity of the opossum (Didelphis marsupials) towards the 
venom of the Jararaca (Bothrops jararaca) snake [49]. Plants are 
reputed to be capable of neutralizing the action of snake venom, 
and their antivenom activity has been related to certain 
chemical compounds identified in those plants [43]. Several 
chemical constituents like alkaloids, flavonoids, sitosterol or 
glucoside, lupeol, gymnemagenin, phenolics, pentacyclic 
triterpenes like oleanoic acid, ursolic, tannins, taraxasterol, α 
and β amyrin are found to be present in varying proportions in 
plants. They have also been previously reported for antisnake 
venom activity. All these classes of chemical compounds are 
capable of interacting with macromolecular targets with 
enzymes or receptors and it can effectively inhibit the toxic 
effect of snake venoms in vitro than in vivo [50]. Besides, several 
other phytochemicals of plant origin showed the most potent 
inhibition of human synovial fluid phospholipase (HSF- PLA2) 
was observed with compounds such as scalaradial and ellagic 
acid, which both have IC50 values of 0.02 µM (using autoclaved 
[3H]-arachidonic-acid (AA)-labelled Escherichia coli membranes 
as substrate). 
  
b) Alkaloids  
Recently, alkaoid has been reported that aristolochic acid 
inhibits PLA2 in vitro and also decrease both oedema induced 
by snake venom as well as human synovial fluid PLA2 (Figure 
1B). Several authors studied the anti-inflammatory activity of 
aristolochic acid and to investigate the effect of the alkaloid on 
the enzymes involved in the release of eicosanoids. Results 
demonstrated that aristolochic acid was inhibited the 
inflammation induced by immunological, immune complexes, 
and non-immunological agents such as carrageenan or croton 
oil [51]. 
 
c) Flavonoids  
The inhibitory effect of the plant flavonoid and rutin were 
investigated against group I PLA2 from porcine pancreas and 
Naja naja a s  w e l l  a s  g r o u p  I I  P L A 2s from Vipera russelli and 
Crotalus atrox etc (Figure 1C). Rutin efficiently inhibited group 
II PLA2s obtained both V. russelli and C. atrox but it was shown 
only a weak inhibitor of PLA2-I from porcine pancreas and N. 
naja. The lack of strong inhibition of pancreatic PLA2-I was not 
due to contaminating proteins in the enzyme preparation, since 
the same weak inhibition was obtained against pancreatic PLA2 
purified to homogeneity as well [52]. The phytotherapeutic 
agent like flavonoids selectively inhibited the group II PLA2 of 
venom origins. Previously, Alcaraz and Hoult [53] reported that 
the hypolaetin-8-glucoside and related flavonoids inhibited the 
snake venom phospholipase A2 effectively. Porcine pancreatic 
PLA2 hydrolyses phosphatidylcholine when in the lamellar 
state as well as in the micellar state. We have found that alpha-
tocopherol, the most active form of vitamin E, is able to inhibit 
PLA2 activity only toward lamellar fluid membranes, thus 
protecting phospholipids toward this lytic enzyme. This 
compound decreases both the initial rate and the extent of 
hydrolysis. The inhibition is of the non-competitive type and 
the evidence strongly suggests that it is mainly due to an effect 
of alpha-tocopherol on the substrate, i.e. the membrane and not, 
on the enzyme [54]. BIOINFORMATION  open access 
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d) Lipids  
Membrane lipid-derived second messengers are generated by 
PLA2 during synaptic activity. Overstimulation of this enzyme 
during neurotrauma results in the accumulation of bioactive 
metabolites such as arachidonic acid, oxygenated derivatives of 
arachidonic acid, and platelet-activating factor (PAF). Several of 
these bioactive lipids participate in cell damage, cell death, or 
repair-regenerative neural plasticity. Neurotransmitters may 
activate PLA2 directly when linked to receptors coupled to G 
proteins and/or indirectly as calcium influx or mobilization 
from intracellular [55]. Chronic inflammatory diseases are often 
accompanied by intense angiogenesis. A model of 
inflammatory angiogenesis is the murine air pouch granuloma 
which has a hyperangiogenic component. Proinflammatory 
lipid mediator generation is also a hallmark of chronic 
inflammation and the role of endogenous production of these 
mediators in angiogenesis is not known. The 14 kDa PLA2 
deacylates phospholipid, liberating arachidonic acids are used 
for leukotriene and lysophospholipid, production of platelet-
activating factor (PAF) [56]. Another report, 1-alkyl ether lipids 
were studied for their ability to inhibit PLA2 and antagonize 
PAF responses. Studies with synthetic micellar substrate (1-
stearyl-2-arachidonyl phosphocholine), at concentrations 
ranging from 0.02 to 1000 µM, demonstrate that CL 118326 
inhibits porcine pancreatic PLA2  in vitro. As the substrate 
concentration increases, there is a dose-dependent increase in 
the IC50 value (IC50 ranges: 2.6-137 µM). CL 118326 inhibits 
mammalian pancreatic PLA2, but not snake or bee venom PLA2. 
CL 118326 inhibits thrombin effectively at IC50 = 7.9 µM dose 
[57]. 
 
Phospholipase A2 (PLA2) inhibitors from marine organisms: 
Phospholipase A2 (PLA2) inhibitor from marine organisms that 
are provides a rationale for seeking inhibitors of PLA2 as anti-
inflammatory agents [58]. Marine natural products that inhibit 
PLA2 are manoalide [59-63] and its derivatives such as 
scalaradial  [64] and related compounds like pseudopterosins 
[65], vidalols, and a group of terpenoids that contain masked 
1,4-dicarbonyl moieties respectively. 
 
a) Manoalide 
Several marine terpenoids that contain at least one reactive 
aldehyde group, such as manoalide (MLD) and its congeners, 
possess interesting anti-inflammatory activities that are 
mediated by the covalent inactivation of secretory 
phospholipase A2 [63]. Manoalide is a potent analgesic and anti-
inflammatory sesterterpene isolated in 1980 from a marine 
sponge. The anti-inflammatory activity of manoalide is due to 
inhibition of PLA2, through irreversible binding to several 
lysine residues (Figure 1D). This binding is realized by means 
of the two masked aldehyde functions present in the polar part 
of manoalide. Of the two aldehyde groups, only that present in 
the g-hydroxybutenolide ring seems to be essential, since 
cacospongionolides, naturally occurring analogues lacking the 
second masked aldehyde group, were also shown to be 
irreversible PLA2 inhibitors. It appears that the minimum 
structural requirement for exhibiting manoalide-like PLA2 
inhibition would be the presence in the inhibitor of functional 
groups able to seize the amino groups of PLA2 lysine residues 
with formation of stable covalent bonds. Many manoalide 
analogues have been isolated from marine sponges, most of 
them sharing PLA2 inhibitory properties [62]. 
MLD inactivated bee venom phospholipase A2s, localization of 
the manoalide binding site on bee venom PLA2 [59-60]. MLD 
drug inhibited purified human synovial fluid phospholipase A2 
(HSF-PLA2). Inhibition of HSF-PLA2 by MLD was concentration 
and time dependent with IC50 values of 0.2 and 0.02 µM for 
dipalmitoylphosphatidylcholine  (DPPC) as the substrate (38.0 
µM and 18.8 µmol) [3H]arachidonic acid released/min/mg 
protein with Escherichia coli as a natural substrate respectively 
[61]. 
 
b) Scalaradial  
Scalaradial (SLD), a 1, 4-dialdehyde marine terpenoid that was 
isolated from the sponge (Cacospongia mollior) possesses anti-
inflammatory properties in vivo and in vitro. SLD is a potent 
inactivator of bee venom PLA2 with an IC50 value of 0.07 µM. 
Inactivation of bee venom PLA2 occurred in a time-dependent 
manner. The rate of inactivation was reduced markedly in the 
presence of excess phosphatidylcholine, suggesting that 
modification of the enzyme occurs at or near the substrate 
binding site [64]. Due to its peculiar dialdehyde structural 
feature, it has been proposed that scalaradial exerts its 
enzymatic inactivation by means of an irreversible covalent 
modification of its target [63]. 
 
c) Petrosaspongiolide 
Petrosaspongiolide M (PM) is an anti-inflammatory marine 
metabolite that displays a potent inhibitory activity toward 
group II and III secretory phospholipase A2 (PLA2) enzymes. 
The details of the mechanism, which leads to a covalent adduct 
between PLA2 and gamma-hydroxybutenolide-containing 
molecules such as PM. The model provides an interesting 
insight into the PM-PLA2 inhibition process and may prove 
useful in the design of new anti-inflammatory agents that target 
PLA2 secretory enzymes [65]. 
 
d) Vidalols  
Chemical studies of the Caribbean red alga Vidalia obtusaloba 
have resulted in the isolation of two new bromophenolic 
metabolites, vidalols A and B (1, 2). The new compounds were 
discovered as part of an organized effort to isolate new 
naturally-occurring anti-inflammatory agents with a focus upon 
those which may function through the inhibition of PLA2 [66]. 
A chemically synthesized novel phenolic metabolite, 
vidalenolone, as well as two previously described and 
structurally simple phenols were isolated as SH2-inactive 
substances. Their structures were determined by spectroscopic 
methods such as 2D NMR [67]. The cytotoxic activities of all the 
synthetic compounds were determined against DLD-1 cells 
using the MTT assay. Compounds with IC50 < 20 µmol were 
also tested against HCT-116 cells. Compound 3c (2, 5-dibromo-
3, 4-dihydroxybenzyl n-propyl ether) was the most active 
compound against both cell lines (IC50 = 1.72 and 0.80 µmol, 
respectively), and its effect on the cell cycle was studied using 
flow cytometry [68]. 
 
Other lead molecules as PLA2 inhibitors: 
Analogues of lead molecules were generated by substituting 
different types of functional groups in order to obtain a 
molecule with optimal PLA2 inhibition. The lead molecules 
characterized as PLA2 inhibitors are acenaphthenes, 
azetidinones, indoles, piperazines, isoxazolidines, isoxazolines, 
diazepinones, and several substrate analogues [69]. Among BIOINFORMATION  open access 
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these analogue piperazine derivatives on optimization with 
respect to hydrophobicity and electronegativity showed 
inhibition at nanomolar levels. Structural analysis of many lead 
molecules indicated that a PLA2 inhibitor should have both 
hydrophobic moiety and polar functional groups. However, the 
docking studies clearly showed that the binding mechanisms of 
plant (acalyphin, chlorogenic acid, stigmasterol, curcumin and 
tectoridin) and marine compounds (gracilin A and 
aplysulphurin A), performed with Russell’s viper and bovine 
pancreatic PLA2 as target molecules. These compounds 
interacted with the amino acid (AA) residues at the active site of 
both PLA2s, and proved the efficacy as anti-inlfammaotry and 
as well antidotes properties [70]. 
 
Antibiotic as a PLA2 inhibitor 
a) Tetracyclines as PLA2 inhibitor  
Tetracyclines are primarily bacteriostatic broad-spectrum 
antimicrobial agents; they are thought to exert their effect by the 
inhibiting protein synthesis. Tetracyclines at low doses were 
found to interfere with the production of prostaglandins and 
leukotrienes  [71-72], scavenge oxygen radicals [73], interfere 
with the expression of nitrous oxide synthase [74], and enhance 
natural inhibitors of matrix metalloproteinases [75-76] after this 
novel discovery non-antimicrobial chemically modified 
tetracyclines (CMT) were prepared and widely investigated in 
different type of diseases (Figure 1E). 
 
Tetracyclines have been recognized as useful agents for therapy 
of inflammatory arthritis [77], non-infected corneal ulcers, 
serious (sometimes life-threatening) skin-blistering diseases, 
rheumatoid arthritis and osteoarthritis, systemically as well as 
locally induced bone loss, suppress connective tissue 
breakdown during periodontal disease and perhaps even 
tumor-induced angiogenesis [78-80]. However, prolonged use 
of tetracyclines is limited by their detrimental antimicrobial 
properties. Recently, a group of chemically modified 
tetracyclines CMT, CMT-3 and CMT-5 [81] devoid of 
antimicrobial properties has been synthesized. However, the 
CMT-3 (COL-3) is produced by deletion of the dimethylamino 
group from carbon 4 in the A ring of tetracycline, which 
abolishes the antibiotic activity but not the anti-MMP activity of 
the molecule. Further modification by replacement of the 
carbon 11 carbonyl oxygen and the carbon 12 hydroxyl groups 
with nitrogen, abolishes the anti-MMP activity, giving rise to 
CMT-5 (COL-5), which is neither antibiotic nor anti-MMP [79]. 
Some CMT were found to inhibit various matrix-
metalloprotinase (MMPs) [79, 82, 83]. Nearly 10 synthetic CMT 
were tested for inhibition of sPLA2 human porcine PLA2, and 
Naja naja PLA2. PLA2 activity was assessed by radio labeled 
Escherichia coli assay using standard and high calcium 
concentrations. Of which 6 CMT inhibited sPLA2 activity at 50 
µg/ml or lower concentrations [77]. However, the other 
antibiotics such as tetracyclines, macrolides, chloramphenicol 
and carbenicillin inhibited the activity of Crotalus adamanteus 
PLA2 towards phospholipids of egg-yolk emulsions [84]. For 
example, an assessment of metalloproteinase inhibitors 
clodronate and doxycyline showed effective neutralization of 
hemorrhage and coagulopathy induced by Bothrops asper snake 
venom [85]. 
 
Tetracyclines also inhibit cell proliferation, cell migration, and 
synthesis of the extracellular matrix in a variety of cell types 
studied in culture [86]. However, the earlier studies have shown 
that CMT-3 and CMT-8 inhibit tumor metastasis and arthritis-
affected synoviocyte invasion in animal models [87]. In 
addition, doxycycline, CMT-1, and CMT-8 exerted a direct 
dose-dependent inhibition of porcine periodontal ligament 
epithelial cell medium MMP activity as assayed by gelatin 
enzymography. Both the 92-kDa (MMP-9) and 72-kDa (MMP-2) 
gelatinases were inhibited by the tetracyclines added to the 
conditioned medium. Culturing the cells in the presence of the 
tetracyclines required considerably smaller concentrations to 
reduce the secreted MMP activity. The drugs were not toxic to 
the epithelial cells at 4 to 250 µg/ml concentrations up to 24 h of 
culture. Doxycycline and the chemically modified tetracyclines, 
in addition to inhibiting the MMP activity may also reduce the 
enzyme expression at the transcriptional level [88]. Doxycycline 
and 4-de-dimethylaminotetracycline (CMT-1) have been tested 
in vitro for their ability to inhibit human neutrophil and 
fibroblast interstitial collagenases and collagenase in human 
gingival crevicular fluid (GCF). Human fibroblast collagenase 
and GCF collagenase from LJP patients were both relatively 
resistant to tetracycline inhibition; the IC50 for doxycycline and 
CMT-1 for these 2 sources of collagenase were 280 and 500 µM, 
respectively [89-90]. The presence of 25 μM CMT-3, the 48/80-
induced histamine release from rat serosal mast cells was 
inhibited significantly, to 43.0 ± 7.3% of control. Similarly, the 
activation-induced secretion of TNF-α and IL-8 by HMC-1 cells 
were decreased in the presence of 25 μM CMT-3 to 13.5 ± 4.1% 
and 9.7 ± 1.1% of control, respectively [91]. Adding CMT-3 at 
final concentrations of 5 - 20 µM inhibited MT1-MMP 
gelatinolytic and caseinolytic activity, blocked MT1-MMP 
activation of pro-MMP-2, and decreased invasiveness (using the 
Matrigel system) of HT-1080 fibrosarcoma cells [92]. Six 
different CMT to inhibit human and chicken MMP were studied 
in vitro. The ability of tetracycline and its analogs to inhibit 
MMP appears to depend on the Ca++/Zn++ binding site at C11 
(carbonyl oxygen) and C12 (OH group) of the molecule, which 
is lacking in CMT-5, the pyrazole derivative of tetracycline [93]. 
 
b) Lipophilic tetracyclines such as minocycline and doxycycline 
Previous study reported that the doxycycline, minocycline [74], 
and chemically modified tetracyclines (CMTs) [94] inhibit 
inducible NO synthase (iNOS) expression in murine 
macrophages. Tilley and colleagues [95], reported that the 
tetracyclines, particularly minocycline and doxycycline, are 
potent inhibitors of collagenases and gelatinases, two matrix 
metalloproteinases  [96, 97] showed a significant reduction of 
the collagenolytic activity of synovial tissue obtained from six 
patients with rheumatoid arthritis who received minocycline 
before total joint arthroplasties compared with the 
collagenolytic activity of synovium obtained from the same 
patients during a previous arthroplasty when they had not 
received minocycline. Minocycline and doxycycline also inhibit 
PLA2 in vitro [77, 98], another mediator of inflammation [99]. 
Tetracycline has also been reported to decrease leukotaxis and 
to inhibit phagocytosis by neutrophils, lymphocyte proliferative 
responses, and anti-CD3-induced synovial T-cell proliferation 
in a dose-dependent manner [79, 100]. Some of these anti-
inflammatory properties have been shown in a chemically 
modified tetracycline analog that has no antibacterial effects 
[79,101,102]. Recently, several in vitro and fewer in vivo studies 
have shown that tetracyclines, non-antibacterial, non-chelating 
hydroxypyrazoline derivative of minocycline, 12 S-hydroxy-1, BIOINFORMATION  open access 
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12-pyrazolinominocycline (PMIN), also induced antinociceptive 
and anti-inflammatory effects in rats [103]. 
Cazalis et al, [104] investigated that the effects of tetracycline 
(TC), doxycycline (doxy), and chemically modified tetracycline-
3 (CMT-3) on the production of pro-inflammatory mediators 
and MMPs in an ex vivo human whole blood (WB) model 
stimulated with Porphyromonas gingivalis lipopolysaccharide 
(LPS). Results show that TC, doxy, and CMT-3 can reduce the 
production of pro-inflammatory mediators (interleukin-1beta 
(IL-1beta), interleukin-6 (IL-6), interleukin-8 (IL-8), MMP-8, and 
MMP-9. However, the secretion of IL-1beta and -8 and TNF-
alpha by macrophages decreased significantly (P <0.05) when 
they were pretreated with 2 µM doxycycline, whereas a 
concentration of 10 µM was required to significantly reduce IL-6 
secretion [105]. Pretreatment of macrophages with 10 µM 
doxycycline prior to A. actinomycetemcomitans LPS 
stimulation resulted in a marked decrease in the 
phosphorylation of extracellular signal-regulated kinase 1/2 (-
76%). 
 
A previous study describes the interaction of α-Lipoic acid 
(ALA) and dihydrolipoic acid (DHALA) with pro-inflammatory 
secretory PLA2  enzymes from inflammatory fluids and snake 
venoms. In vitro enzymatic inhibition of sPLA2 from V. russellii, 
N. naja and partially purified sPLA2 enzymes from human 
ascitic fluid (HAF), human pleural fluid (HPF) and normal 
human serum (HS) by ALA and DHLA was studied [106]. Since 
in experimental models lipophilic tetracyclines such as 
minocycline and doxycycline are anti-inflammatory, they 
examined their effects on PLA2 activity using two assay systems 
in vitro. They found that minocycline and to a lesser degree 
doxycycline were markedly inhibitory to both pancreatic and 
non-pancreatic PLA2. Using [14C] oleic acid labeled Escherichia 
coli membrane phospholipids as substrate, the IC50 values for 
minocycline and doxycycline were 3.6 x 10-5 M (18 µg/ml) and 
0.98 x 10-4 M (47 µg/ml), respectively [77]. In addition, 
minocycline has its greatest effect on lipid types, which result 
from degradation (lipase) reactions, suggesting a lipase 
inhibition effect and/or direct effect on ocular flora [107]. 
Currently, patients were randomized to receive 20 mg of 
subantimicrobial-dose (SD) doxycycline or placebo twice daily 
for 6 months. Doxycycline treatment significantly reduced the 
number of inflammatory and non-inflammatory lesions in 
patients with moderate facial acne, was well tolerated, had no 
detectable antimicrobial effect on the skin flora, and did not 
result in any increase in the number or severity of resistant 
organisms [108]. 
 
Snake venom PLA2 inhibitors and therapeutic potential: 
Certain molecules like endogenous antitoxic serum proteins 
with neutralizing capacity against snake venoms have been 
previously reported [109, 110]. Snake blood-derived inhibitors 
have been grouped into three major classes (α, β and γ), based 
on common structural motifs found in other proteins with 
diverse physiological properties [111-114]. PLA2 inhibitors 
(PLIs) from snake blood Agkistrodon, Trimeresurus, Bothrops, 
Crotalus, Naja, Laticaudata and Elaphe. Several reviews dealing 
with inhibitors of snake venom hemorrhagins [115-120] 
myotoxins and neurotoxins [121] have been published along the 
past two decades. Lizano et al.  [114] reviewed the current 
knowledge regarding PLA2s inhibitor proteins derived from 
both snake and mammalian blood, with particular emphasis on 
the classification, molecular and functional characterization of 
myotoxic PLA2 inhibitors. 
 
The search for new strategies for treatment of snake 
envenomations has prompted the discovery of proteins which 
neutralize the major toxic components of these venoms. These 
proteins have been isolated from both venomous and non-
venomous snakes, mammals, and most recently from medicinal 
plant extract [114]. Phospholipases A2s (PLA2s) are commonly 
found in snake venoms from Viperidae, Hydrophidae and 
Elaphidae families have been extensively studied due to their 
pharmacological and physiopathological effects in living 
organisms  [122]. Several substances have been evaluated 
regarding their effects against snake venoms and isolated 
toxins, including plant extracts and compounds from marine 
animals, mammals and snakes serum plasma, in addition to 
poly or monoclonal antibodies and several synthetic molecules. 
The enzyme first attracted the interest of investigators seeking 
cures for snake-bite, since it is a component of toxic venoms 
from a number snakes. These venoms produce neurotoxicity, 
myotoxicity, and inflammation. Interestingly, some non-
venomous snakes secrete PLA2 inhibitors. Venomous snakes 
produce a natural PLA2 inhibitor that has also been isolated. 
Neuroprotective polypeptide (diffusible survival evasion 
peptide or DSEP) was used to treat rats with traumatic brain 
injuries. The peptide, which inhibits the enzymatic activity of 
sPLA2, blocked the inflammatory response to injury and 
prevented neural degeneration [123]. Furthermore, the 
biotechnological potential of PLA2 inhibitors may provide 
therapeutic molecular models with antiophidian activity to 
supplement the conventional serum therapy against these 
multifunctional enzymes. 
 
a) PLA2 inhibitors peptides 
A basic nonapeptide P2 (antiflammin-2, HDMNKVLDL) which 
is identical to a portion of the amino acid sequence (residues 
246-254) of lipocortin I, has been described to have 
antiinflammatory activity in a rat paw edema model [124]. P2 
(0.05 µM) was also reported to inhibit porcine pancreatic PLA2. 
The effect of synthetic P2 (98% pure) on PLA2 was evaluated in 
two assay systems. Using porcine pancreatic PLA2 and 
phosphatidylcholine/deoxycholate mixed micellar substrate, P2 
(0.005-50 µM) had no effect on PLA2 activity, even in the 
presence of 2 [125]. Two anti-inflammatory peptides, named 
antiflammins (AFs), corresponding to a region with high amino 
acid similarity between lipocortin-1 and uteroglobin were 
tested for their ability to inhibit transglutaminase (TG) and low-
molecular-mass PLA2. Porcine pancreatic PLA2 activity and 
guinea pig hepatic TG activity were determined by arachidonyl 
release from arachidonyl-phosphatidylcholine and by the 
incorporation of putrescine into succinylated casein, 
respectively. AFs inhibited TG activity but did not affect PLA2 
activity. Moreover, porcine pancreatic PLA2 was activated by 
TG [126]. This antiflammins showed significant effects on PLA2 
activation by the enzyme called transglutaminase. However, the 
peptides (antiflammins) failed to show their inhibit effect 
against purified human synovial fluid PLA2 (HSF-PLA2), even 
at such high concentrations of peptides as 50 µM. In vivo anti-
inflammatory activity of these peptides was evaluated in 
several experimental models of inflammation induced by 
carrageenan, croton-oil [127].  
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b) Co-crystallization studies PLIs  
In 1984, the first venom PLA2 with a lysine substituting for the 
highly conserved aspartate 49 was discovered, in the North 
American crotalid snake Agkistrodon piscivorus piscivorus [128]. 
Ten years later, the first mapping of a 'toxic region' on a Lys-49 
PLA2 was reported, in B. asper myotoxin II [129]. After a further 
decade of research on the Lys-49 PLA2s, a better understanding 
of their structural determinants of toxicity and mode of action is 
rapidly emerging, with myotoxic effector sites identified at the 
C-terminal region in at least four proteins: B. asper myotoxin II, 
A. p. piscivorus (K49 PLA2),  A. contortrix laticinctus (ACL 
myotoxin), and B. jararacussu (bothropstoxin I) [130].  
 
A new myotoxic Lys49-PLA2 isolated from B. moojeni snake 
venom has been crystallized. Suggest a new quaternary 
structure for this Lys49-PLA2 i n  c o n t r a s t  t o  t h e  d i m e r i c  a n d  
monomeric structures solved so far for this class of proteins 
[131,132]. BnSP-7 and BnSP-6, Lys49-PLA2 isolated from B. 
neuwiedi pauloensis snake venom, were co-crystallized with 
alpha-tocopherol and X-ray diffraction data were collected for 
both complexes (2.2 and 2.6 A). A new "alternative" quaternary 
conformation for these two complexes compared with all other 
dimeric Lys49-PLA2 has been observed [133]. Large single 
crystals of piratoxin I a Lys49-PLA2 homologue with low 
enzymatic activity have been obtained. The crystals belong to 
the orthorhombic system space group P2 (1)2(1)2(1), and 
diffract X-rays to a resolution of 2.8 A. Preliminary analysis 
reveals the presence of two molecules in the crystallographic 
asymmetric unit [134]. A myotoxic PLA2, bothropstoxin II, 
which exhibits low hydrolytic activity, was crystallized and X-
ray diffraction data were collected to a resolution of 2.2 A. 
Preliminary analyses reveals the presence of three molecules in 
the asymmetric unit. 
 
c) Structure based functional studies of PLIs 
Several crystal structures of the tetrahedral mimic inhibitors 
with an sn-2-phosphate, substituent, L-1-(O-octyl-2-(heptyl 
phosphonyl)-sn-glycero-3-phosphoethanolamine, complexed 
with secreted PLA2 from Chinese cobra venom [135, 136], PLA2 
and peptide inhibitor from Russells viper venom [137], bee 
venom [138, 139], and inflammatory exudates [140, 141] have 
been reported. Also the crystal structure of a sn-2-acyl-amino 
analogue of phospholipids complexed with the engineered 
(without the residues of the surface 62-66) porcine PLA2 [142, 
143] has been determined. The crystal structures of the 
complexes of bovine pancreatic PLA2 with an inhibitor n-
dodecyl-phosphorylcholine [144-147] and human synovial PLA2 
with an acyl amino analogue of phospholipids [148] are also of 
some interest. Recently, a series of indole inhibitors of human 
secretory PLA2 were developed [149-151]. 
 
Despite differences in their primary sequences (~30% homology 
only), crystal structures of PLA2 from bovine pancreas (type I) 
and human synovial fluid (type II) are almost superimposable 
and, not surprisingly, the active sites from both types of 
enzymes are virtually identical [152]. Asp-99 and His-48 form 
an essential catalytic dyad in the fashion of serine proteases 
[153]. Tyr-52 and Tyr-73 appear to be associated with these two 
residues via a hydrogen bonding network, but there is evidence 
[154] that Tyr-52 is not essential for the catalytic reaction. From 
structure-function studies of type I and II enzymes, the first 
eight residues at the NH2 terminus together with Tyr-69, based 
on the numbering system of Renetseder et al, [155], are thought 
to play a functional role in interfacial binding of the enzyme to 
aggregated substrate [156]. Both chemical modification [157] 
and site-directed mutagenesis [158-160] studies have shown 
that the NH2-terminal residue is crucial for activity on micellar 
substrates. Further studies with type I PLA2  [160, 161] have 
shown that significant alterations of the invariant hydrophobic 
face of the NH2-terminal amphipathic helix (residues 2, 5, or 9) 
are detrimental to enzyme activity. Residue 10 is necessary for 
interfacial binding, and changes in other residues have a 
modest or no effect on catalytic activity. Production of the fully 
active enzyme depends on conformational changes of the NH2-
terminal helical region that occur firstly on interfacial binding to 
the phospholipid micelle and secondly on substrate binding at 
the active site [162]. 
  
Nuclear magnetic resonance (NMR) spectroscopic studies of 
porcine pancreatic PLA2 indicated that the first few residues of 
the NH2 terminus are not alpha-helical in solution but become 
helical and rigid on formation of a ternary complex with 
micelles or a substrate analogue [163-165]. X-ray 
crystallographic studies showed that the NH2-terminal and β-
loop regions (residues 62-73) are held by hydrogen bonding in 
the active enzyme conformation and form the catalytic network 
involving His-48, Tyr-52, Tyr-73, and Asp-99 [166-169]. Recent 
studies have shown that there is a strong but non-covalent 
association between residues of the NH2-terminal amphipathic 
helix and the β-loop region, suggesting that a novel approach to 
enzyme inhibition may be to provide one or another of these 
domains as free peptide. Peptides from the β-loop region, 
corresponding to residues 70-74 in three different type II PLA2 
molecules, were made and added to mixed micelle assays for 
the PLA2. Significant enzyme inhibition occurred for each of the 
three peptides, and inhibition was specific to the PLA2 from 
which the peptide was derived. 
 
Mechanism action of PLA2 inhibitors: 
 
 
Figure 2: Flow chart represents the simple mechanism of action 
of inhibitors on interleukin (IL) induced expression of secretory 
phospholipase A2 (sPLA2) and matrix metalloproteinase. 
Cytokines induced the expression of sPLA2-IIA and MMP via 
activation of mitogen-activated protein kinase (MAPK) etc. BIOINFORMATION  open access 
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Natural inhibitor inhibits p38 MAPK phosphorylation and 
slows down the activation of transcription factor which control 
the transcription of sPLA2, MMPs and inflammatory cytokines. 
MAPKK –kinase, sPLA2-IIA-secretory phospholipase A2 Group 
IIA, PGE2-prostaglandin E2. 
 
Secretory phospholipase A2 (sPLA2-IIA) is an inflammatory 
protein known to play a role in the pathogenesis of 
e n v e n o m a t i o n .  O v e r  t h e  l a s t  3 0  y e a r s ,  i n t e r e s t  i n  P L A 2 has 
grown beyond its enzymatic capacity to cleave phospholipids. 
PLA2 cleave membrane phospholipids to release arachidonic 
acid, the precursor to a large family of pro-inflammatory 
eicosanoids including prostaglandins and leukotrienes. Current 
therapies include non-steriodal anti-inflammatory drugs 
(NSAIDs') that inhibit cyclooxygenases (COX-1, COX-2) but 
have no effect on the production of leukotrienes or platelet 
activating factor (PAF) [170, 171]. In addition, existing treatment 
with non-steroidal drugs is the only choice for the treatment of 
anti-inflammatory. However, the available treatments (such as 
targeting tumour necrosis factor and TNF signaling) do not cure 
the disease in the clinical settings, and ultimately leads to 
adverse side effects [172]. A simple mechanism of action of 
inhibitors on interleukin (IL) induced expression of sPLA2 and 
matrix metalloproteinase proposed. Cytokines induced the 
expression of sPLA2-IIA and MMP via activation of mitogen-
activated protein kinase (MAPK) etc. Natural inhibitor inhibits 
p38 MAPK phosphorylation and slows down the activation of 
transcription factor which control the transcription of sPLA2, 
matrix metalloproteinase (MMP) such as MMP-1, MMP-2, 
MMP-3 and MMP-9 and inflammatory cytokine like IL-1, IL-6 
and TNF -alpha etc. The effects of inhibitors inhibit the sPLA2 
action and decrease the formation of arachidonic acid for 
prostaglandin production (Figure 2). 
 
Conclusions and future impacts: 
Snakebite envenomations and their severity remain is not clear 
yet. However, this poorly neutralized by conventional 
antivenom serotherapy. In severe cases, these local effects may 
lead to permanent tissue loss, disability or amputation. A 
renewed interest in the phenomenon of inter- and intra-species 
resistance towards the toxicity of snake venoms, coupled with 
the search for new strategies for treatment of snake 
envenomations, has prompted the discovery of proteins which 
neutralize the major toxic components of these venoms. 
Naturally available inhibitors occupy an important place in the 
potential to neutralize the toxic effects caused by snake venom 
proteins. It has been well recognized for several years that 
animal sera, some plant and marine extracts, antibiotics from 
synthetic chemicals are the most potent in neutralizing snake 
venoms. The implications of these new groups of PLA2 toxin 
inhibitors in the context of our current understanding of snake 
biology as well as in the development of novel therapeutic 
reagents in the treatment of snake envenomations world-wide 
are discussed. Furthermore, the biotechnological potential of 
PLA2 inhibitors may provide therapeutic molecular models 
with antiophidian activity to supplement the conventional 
serum therapy against these multifunctional enzymes. In 
addition to that the clinically importance of these natural 
inhibitors may lead to the development of new novel 
antivenoms therapeutics for the efficient treatment of the 
envenomation. 
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